Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eukaryotic translation initiation factor 3 subunit J (EIF3J) is a core component of the eukaryotic translation initiation factor 3 (eIF3) complex, which orchestrates the initiation of protein synthesis in eukaryotic cells[2][4]. EIF3J binds the eIF-3 complex through EIF3B and locates at the aminoacyl site and mRNA entry channel of the 40S ribosomal subunit, placing it in the ribosomal decoding center[1][3]. It modulates access to the mRNA-binding cleft, interacts with other initiation factors (notably eIF1A), and is essential for multiple steps of initiation, including the recruitment of mRNA to the ribosome, assembly of the pre-initiation complex, and regulation of scanning for the start codon[1][2][3]. EIF3J also cooperates in translation termination by stimulating peptidyl-tRNA hydrolysis in conjunction with release factors and participates in ribosomal recycling[3]. While critical for correct translational control, it is not a direct therapeutic target nor a clinical biomarker, but its indirect influence on cell proliferation, differentiation, and apoptosis links it to fundamental cellular processes[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eukaryotic translation initiation factor 3 subunit J (EIF3J).